Last reviewed · How we verify
NCT04573335
Diabetes Outcomes in COVID-19 Pandemic
trial in Diabetes in 1,282 participants. Completed in 30 July 2020.
15 July 2020
Quick facts
| Lead sponsor | Services Institute of Medical Sciences, Pakistan |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,282 |
| Start date | 1 June 2020 |
| Primary completion | 15 July 2020 |
| Estimated completion | 30 July 2020 |
| Sites | 1 location across Pakistan |
Conditions studied
- Diabetes — all drugs for Diabetes →
- Covid19 — all drugs for Covid19 →
- Isolation, Social — all drugs for Isolation, Social →
Sponsor
Services Institute of Medical Sciences, Pakistan
Who can join
Adults 18 to 70, any sex, with Diabetes or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetes management and follow-up has become a challenge during the COVID-19 pandemic. Nation-wide lockdowns and social distancing measures adopted in an attempt to break the chain of COVID-19 transmission have significantly disrupted routine care and follow-up of diabetes. In the health sector, especially in low-income countries such as Pakistan, there has been a shift of resources and staff reassignment from stable chronic illnesses to support COVID-19 pandemic. Disruption of routine outpatient health services and travel restrictions increase the risk of worsening diabetes control and diabetes-related health outcomes. Additionally, social isolation amidst an atmosphere of fear and uncertainty contributes to stress further affecting glycaemic control.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04573335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Services Institute of Medical Sciences, Pakistan trials
Trials by the same sponsor.
- NCT07274319 — EFFICACY OF TRANSMUCOSAL MINIPLEITE STABILIZATION TECHNIQUE VERSUS INTRA-ARCH WIRE STABILIZATION TECHNIQUE FOR FIXATION · NA · not yet recruiting
- NCT07238946 — Musculoskeletal Pain and Its Association With Stress in Medical Students · completed
- NCT06720051 — Intraosseous Versus Submucosal Dexamethsone Injection in Third Molar Surgery · NA · not yet recruiting
- NCT07243977 — Comparison of Microneedling Along With Topical Vitamin D3 Versus Microneedling in Alopecia Areata · NA · active not recruiting
- NCT06622642 — Efficacy of Transoral Versus Transbuccal Technique for Fixation of Mandibular Angle Fracture · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04573335 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Services Institute of Medical Sciences, Pakistan
- Last refreshed: 5 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04573335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing